title: Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY).
abstract: The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.
authors.forename: U
authors.initials: U
authors.lastname: Lindblad
authors.forename: G
authors.initials: G
authors.lastname: Lindberg
authors.forename: N-O
authors.initials: NO
authors.lastname: Månsson
authors.forename: J
authors.initials: J
authors.lastname: Ranstam
authors.forename: M
authors.initials: M
authors.lastname: Tyrberg
authors.forename: S
authors.initials: S
authors.lastname: Jansson
authors.forename: K
authors.initials: K
authors.lastname: Lindwall
authors.forename: M
authors.initials: M
authors.lastname: Svärdh
authors.forename: L
authors.initials: L
authors.lastname: Kindmalm
authors.forename: A
authors.initials: A
authors.lastname: Melander
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011236:Prediabetic State / Q000188:drug therapy*; D040242:Risk Reduction Behavior; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D013453:Sulfonylurea Compounds